Checkpoint inhibitor therapy has transformed oncology, yet clinical responses remain highly variable. Current explanations rely primarily on static biomarkers, which do not capture the dynamic nature of biological systems. This conceptual note proposes a systems-dynamic reinterpretation: checkpoint therapy does not simply activate the immune system, but perturbs a system positioned within a landscape of stability and transition. T-cell exhaustion is reframed as a stable but reversible state, and treatment response is understood as dependent on system timing and residual plasticity. The paper introduces a central principle: treatment efficacy is not determined solely by mechanism, but by whether intervention occurs within a phase where the system remains capable of transition. This implies the existence of a transient window of reversibility preceding attractor consolidation. Checkpoint therapy is thus interpreted as a real-world example of a broader phenomenon: effective intervention requires detecting loss of stability prior to transition. This work is part of the Timing & Failure series and builds on a systems-level approach to disease as dynamic process rather than static pathology.
Anita Domargård (Fri,) studied this question.